论文部分内容阅读
本文作者初步研究了不同类型肺癌病人血中可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）与药物治疗的相关性，发现肺癌病人血中ｓＩＬ－２Ｒ水平始终高于正常人，差异显著（Ｐ＜０．０１）；各型之间差异不显著；而化疗前后同一病人血中ｓＩＬ－２Ｒ，后者明显高于前者，差异极显著（Ｐ＜０．０１）。提示我们化疗后病人的自身免疫功能降低得更为明显，ＩＬ－２的活性进一步受到抑制。治疗中体外给予ＩＬ－２可否还有待研究。
The authors initially studied the correlation between serum soluble interleukin 2 receptor (sIL-2R) and drug therapy in patients with different types of lung cancer, and found that the level of sIL-2R in blood of lung cancer patients was always higher than normal, with significant differences (P< 0.01); the difference between the various types was not significant; and before and after chemotherapy in the same patient blood sIL-2R, the latter was significantly higher than the former, the difference was extremely significant (P <0.01). It is suggested that the autoimmune function of patients after chemotherapy is reduced more significantly, and the activity of IL-2 is further inhibited. Whether or not IL-2 is administered in vitro for treatment remains to be studied.